Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
HR+
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
•
Primary Care
How do you council patients diagnosed with hormone receptor-positive breast cancer currently or interested in taking exogenous hormones (e.g. testosterone) for gender-affirming treatment?
Related Questions
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
What is your preferred method of surveillance after mastectomy?
